Galectin Therapeutics (GALT) Stock
Biotech company developing galectin inhibitors for liver and cancer. Here's the price, business snapshot, and what's worth knowing about Galectin Therapeutics in July 2026.
Galectin Therapeutics Inc (GALT) is a clinical-stage biotechnology company focused on therapies that inhibit galectin proteins, particularly galectin-3, which are implicated in fibrosis and certain cancers. Its lead candidate, belapectin (GR-MD-02), has been evaluated for non-alcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension and has been explored in oncology combinations. The company has no approved products and its value is closely tied to clinical trial outcomes, regulatory decisions, partnership activity and access to financing. With a market capitalisation near $340 million, GALT is a small-cap, high-volatility stock: investors should expect sharp moves around trial readouts and news. Key risks include clinical failure, regulatory setbacks and dilution from future funding rounds. The company holds intellectual property around galectin inhibitors and has sought collaborations to advance programmes. This summary is educational only and not personal financial advice; investors should assess suitability for their own circumstances and tolerance for speculative biotech risk.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Galectin Therapeutics stock with a target price of $11, indicating growth potential.
Financial Health
Galectin Therapeutics is generating steady cash flow per share, indicating stable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GALT
Liver Disease Therapies | Next-Gen FDA Approvals
The FDA's recent accelerated approval of Gilead's Hepcludex has established the first legal treatment for a deadly liver infection known as hepatitis D. This milestone opens the door for investors to explore opportunities in companies developing innovative liver disease therapies, specialized diagnostics, and advanced patient monitoring systems.
Published: 26 May 2026
Explore BasketNext-Gen Hepatic Therapeutics | Basket Overview
The FDA has granted Gilead Sciences approval for the first-ever treatment targeting chronic hepatitis delta virus. This landmark regulatory decision paves the way for further investments in biotechnology companies developing novel therapeutics for rare and complex liver diseases.
Published: 24 May 2026
Explore BasketMASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: 21 September 2025
Explore BasketMASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: 19 September 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: 18 September 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: 19 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Trial Readouts Matter
Company value often moves on clinical results and regulatory milestones; meaningful readouts can shift sentiment, though outcomes are uncertain.
Targeting Fibrosis
Galectin‑3 inhibition is a novel therapeutic approach to fibrosis and cirrhosis with scientific rationale, but clinical proof of benefit remains necessary.
Funding & Partnerships
As a small‑cap biotech, progress depends on financing and collaborations; watch for potential dilution and partnership announcements.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
